Literature DB >> 21822000

Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study.

Rufino Silva1, M L Cachulo, Pedro Fonseca, Rui Bernardes, S Nunes, Nelson Vilhena, J R Faria de Abreu.   

Abstract

INTRODUCTION: The presence of large-sized drusen (≥125 μm), soft indistinct drusen, pigmentary changes, a large area of drusen and a choroidal neovascular membrane in one eye have been found to be predictive risk factors of late exudative age-related macular degeneration (AMD). Multimodal imaging potentially increases the possibility of indentifying further potential risk factors of developing wet AMD.
PURPOSE: To identify morphological and/or functional baseline risk factors for the development of choroidal neovascularization (CNV) in a multimodal set of images from fellow eyes of patients with exudative AMD.
METHODS: Single-center, prospective, observational, longitudinal 2-year plus 1-year extension study of 62 patients with neovascular AMD in one eye (the nonstudy eye) and early age-related maculopathy (ARM) in the fellow eye (study eye). Best-corrected ETDRS visual acuity, fluorescein angiography (FA) and indocyanine green angiography (ICG), fundus photography, retinal leakage analysis, fundus autofluorescence imaging and optical coherence tomography (OCT Stratus 4.0.2, Carl Zeiss Meditech Inc.) were performed at baseline and every 6 months in order to identify both conversion to CNV as well as possible predictive features present before conversion. A semiautomated computer-assisted grading system was used for classifying fundus color images. Only eyes with 3 years of follow-up were considered for statistical analysis.
RESULTS: Fifty-two patients completed the 3-year study follow-up: 26 men and 26 women aged from 56 to 92 years (mean ± SD: 76 ± 6 years). CNV confirmed with FA developed in 46% of the 52 study eyes during the 3-year follow-up (24 converted eyes: 7 in the first year, 11 in the second and 6 in the third). A significantly higher risk for conversion to wet AMD was found only for leakage on a retinal leakage analyzer (odds ratio, OR = 5.0; 95% confidence interval, CI = 1.5-16.4; p = 0.006) detected at least in one visit before the onset of exudative lesions, for baseline ICG hot spots (OR = 7.2; 95% CI = 2.0-25.7; p = 0.002), baseline late ICG hot spots (OR = 4.7; 95% CI = 1.4-15.4; p = 0.009) and baseline early ICG hypofluorescent spots (OR = 3.7; 95% CI = 1.2-12.1; p = 0.025). The total area of drusen, the area of drusen in subfield 1, inner circle or outer circle, the total number of drusen and the number of drusen ≥125 μm, fundus autofluorescence patterns, OCT findings and the severity of ARM at baseline did not show any correlation with an increased risk of conversion to wet AMD.
CONCLUSION: At 3 years, progression from early to late exudative AMD was superior to the expected rate (44%). ICG early and late hyperfluorescent spots or areas, ICG early hypofluorescent spots or areas and early leakage detected with the retinal leakage analyzer, but not pigmentary changes, large drusen, number and area of drusen at any location or a greater severity of ARM at baseline, showed to be a predictive parameter of conversion to wet AMD.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21822000     DOI: 10.1159/000329473

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  13 in total

1.  [Intravitreal fibrinolysis and retinal vein occlusion].

Authors:  T Bertelmann; T Stief; W Sekundo; M Witteborn; S Strodthoff; S Mennel; N Nguyen; M Koss
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

Review 2.  Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review.

Authors:  M M Castillo; G Mowatt; N Lois; A Elders; C Fraser; W Amoaku; J M Burr; A J Lotery; C R Ramsay; A Azuara-Blanco
Journal:  Eye (Lond)       Date:  2014-09-19       Impact factor: 3.775

3.  Endothelin-1 and Nitric Oxide Levels in Exudative Age-Related Macular Degeneration.

Authors:  Yϋksel Totan; Cemile Koca; Mesut Erdurmuş; Uğurcan Keskin; Ramazan Yiğitoğlu
Journal:  J Ophthalmic Vis Res       Date:  2015 Apr-Jun

4.  Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service.

Authors:  Richard P Gale; Sajjad Mahmood; Helen Devonport; Praveen J Patel; Adam H Ross; Gavin Walters; Louise Downey; Samer El-Sherbiny; Mary Freeman; Simon Berry; Nitin Jain
Journal:  Eye (Lond)       Date:  2019-03       Impact factor: 3.775

5.  Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration.

Authors:  Justus G Garweg
Journal:  Clin Ophthalmol       Date:  2019-07-19

6.  Ocular Risk Factors for Exudative AMD: A Novel Semiautomated Grading System.

Authors:  João Pedro Marques; Miguel Costa; Pedro Melo; Carlos Manta Oliveira; Isabel Pires; Maria Luz Cachulo; João Figueira; Rufino Silva
Journal:  ISRN Ophthalmol       Date:  2013-07-30

Review 7.  Fundus Autofluorescence in Age-related Macular Degeneration.

Authors:  Angelica Ly; Lisa Nivison-Smith; Nagi Assaad; Michael Kalloniatis
Journal:  Optom Vis Sci       Date:  2017-02       Impact factor: 1.973

8.  Fundus Autofluorescence Changes in Age-related Maculopathy

Authors:  Pınar Bingöl Kızıltunç; Figen Şermet
Journal:  Turk J Ophthalmol       Date:  2018-12-27

Review 9.  CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: An Expert Panel Consensus.

Authors:  Tien Yin Wong; Paolo Lanzetta; Francesco Bandello; Bora Eldem; Rafael Navarro; Monica Lövestam-Adrian; Anat Loewenstein
Journal:  Retina       Date:  2020-04       Impact factor: 3.975

10.  Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration.

Authors:  Daniel Ahmed; Martin Stattin; Anna-Maria Haas; Alexandra Graf; Katharina Krepler; Siamak Ansari-Shahrezaei
Journal:  BMC Ophthalmol       Date:  2020-09-25       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.